Figure 4
From: Novel carboxylate-based glycolipids: TLR4 antagonism, MD-2 binding and self-assembly properties
Binding studies on purified hMD-2 receptor. (A) FP13-17 prevent anti-human hMD-2 monoclonal antibody binding in a dose-dependent manner; (B) FP13-17 compete with biotin-LPS for hMD-2 binding; (C) FP13-17 dose-dependently inhibit the binding of bis-ANS to hMD-2;(D)-(H). SPR analysis show direct interaction between FP13-17 and hMD-2; KD values are reported.
